Camidge DR, Kim HR, Ahn MJ, et al. - In assessing treatments for advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer (NSCLC), the first interim analysis in the open-label, phase III ALTA-1L trial showed that the next-generation anaplastic lymphoma kinase (ALK) inhibitor brigatinib had better progression-free survival (PFS) as well as improved health-related quality of life (QoL) vs crizotinib; here researchers describe the findings of the second prespecified interim analysis (150 events). Via randomization, brigatinib 180 mg once daily (7-day lead-in at 90 mg once daily) or crizotinib 250 mg twice daily was administered to patients with ALK inhibitor–naive advanced ALK-positive NSCLC at a 1:1 ratio. Overall, findings demonstrated that brigatinib is a once-daily ALK inhibitor that demonstrated better effectiveness, tolerability, as well as QoL vs crizotinib and, therefore, was concluded as a promising first-line therapy of ALK-positive NSCLC.